Most Undervalued Drug Manufacturers - Specialty & Generic Stocks 2026

Top undervalued Drug Manufacturers - Specialty & Generic stocks in 2026 ranked by Bayesian DCF implied upside. 13-model institutional analysis updated daily.

51 stocks analyzed Updated 2026-05-29
# Ticker Company QOC Price DCF Upside
1 COLL Collegium Pharmaceutical, Inc. 9.2 $33.37 +315.2%
2 AKBA Akebia Therapeutics, Inc. 6.8 $1.05 +257.2%
3 EBS Emergent BioSolutions Inc. 8.3 $9.18 +177.6%
4 PCRX Pacira BioSciences, Inc. 8.7 $23.68 +153.9%
5 TAK Takeda Pharmaceutical Company L 7.4 $16.15 +124.6%
6 AMPH Amphastar Pharmaceuticals, Inc. 10.0 $19.30 +119.6%
7 ASRT Assertio Holdings, Inc. 5.4 $23.44 +116.1%
8 SIGA SIGA Technologies Inc. 10.0 $4.76 +109.7%
9 BHC Bausch Health Companies Inc. 5.8 $5.41 +82.9%
10 BCRX BioCryst Pharmaceuticals, Inc. 6.9 $9.10 +66.7%
11 H••• Haleon ••••• •.• $•••.•• ••.•%
12 P••• Prestige ••••• •.• $•••.•• ••.•%
13 Z••• Zoetis ••••• •.• $•••.•• ••.•%
14 C••• Cronos ••••• •.• $•••.•• ••.•%
15 N••• Neurocrine ••••• •.• $•••.•• ••.•%
16 U••• United ••••• •.• $•••.•• ••.•%
17 A••• Aurora ••••• •.• $•••.•• ••.•%
18 L••• Lantheus ••••• •.• $•••.•• ••.•%
19 C••• Cumberland ••••• •.• $•••.•• ••.•%
20 O••• Organigram ••••• •.• $•••.•• ••.•%
🔒

Unlock the Full Most Undervalued Drug Manufacturers - Specialty & Generic Stocks 2026 List

Screen all 51 Drug Manufacturers - Specialty & Generic stocks with 13 institutional-grade valuation models. Updated daily from SEC EDGAR filings.

Access Full Screening — From $27/mo →

How CirclFi Ranks Drug Manufacturers - Specialty & Generic Stocks

CirclFi analyzes 51 Drug Manufacturers - Specialty & Generic stocks daily using 13 independent institutional-grade valuation models. Each model processes SEC EDGAR 10-K and 10-Q financial filings (700+ XBRL tags), FRED macroeconomic data, and GDELT news sentiment.

The most undervalued drug manufacturers - specialty & generic stocks 2026 ranking uses dcf upside as the primary sort criterion. Models span intrinsic valuation (Bayesian DCF with 10,000 Monte Carlo simulations, EPV), scenario analysis (First Chicago), regime-switching (Markov DDM), and machine learning (ML-RIV, FTNN Topology).